Citigroup Lowers PT on Hospira to $30

Symbols: HSP
Tags: Citigroup
Share

Citigroup has lowered the price target on Hospira (NYSE: HSP) from $39 to $30 and maintains its Neutral rating.


 
 
< Previous
Morgan Stanley Raises PT on Goldman Sachs Group to $130
Next >
UPDATE: Wunderlich Securities Upgrades New Oriental Education to Buy, PT Raised to $42
Share
Printer-friendly version
Send to friend
We're Loving

Benzinga's Premium Memberships

Benzinga's News Delivered Free

Brain Trust